Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Xijing Hospital of Digestive Diseases
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have provided written informed consent
Age 18-75 years;
BMI 17-28 kg/m2
Completed in a PBC study with fenofibrate(NCT06591455)
You may not be if
Coexisting liver disease of other etiologies, including viral hepatitis, chronic alcoholic hepatitis, drug-induced hepatitis, autoimmune hepatitis, hepatocellular carcinoma, etc.;
Transaminases \>5 x ULN or total bilirubin \>3 x ULN;
Pregnant or breastfeeding women, or women planning to conceive during the study period;
Allergy to fenofibrate or ursodeoxycholic acid;
Use of hepatotoxic drugs (e.g., dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than 2 weeks within 6 months before screening, or long-term corticosteroid use;
Variceal bleeding, hepatic encephalopathy, or ascites at diagnosis or previously;
History of severe cardiac, cerebrovascular, renal, or respiratory disease or failure, or psychiatric illness (including psychiatric illness caused by alcohol or drug abuse);
Creatinine \>1.5 x ULN and creatinine clearance \<60 mL/min;
Current use of statins (e.g., pravastatin, fluvastatin, simvastatin), other fibrates (e.g., gemfibrozil, bezafibrate), or structurally related drugs (e.g., ketoprofen);
Planned organ transplantation or previous organ transplantation;
Need for liver transplantation within 1 year according to the Mayo risk score;
Any other condition considered unsuitable for enrollment by the investigator.